[Cervical maturation by repeated applications of prostaglandin E2 gel. 186 cases].
OBJECTIVE
A prospective clinical trial of cervical ripening with intracervical prostaglandin E2 gel in repeated administrations was performed.


METHODS
One hundred eighty-six patients were enrolled in this prospective trial between 01/01/89 and 31/12/93. these patients with unripe cervix (Bishop score < 5) required induction of labor because of pregnancy disorders. Mean patient age was 28.2 years (range 15 to 43), mean gestational age was 39.2 week's gestation (range 33 to 43) and mean parity was 1.8 (range 1 to 10). Our exclusion criterias were as follow: twin pregnancies, breech presentation and premature rupture of membranes. A 0.5 mg prostaglandin E2 gel was administered into the cervix every four hours maximal of three doses before induction of labor with oxytocin. Maternal and neonatal results were reviewed.


RESULTS
Patients required a single dose of gel in 19.9% of cases, two doses in 26.3% and three doses in 53.8%. Induced labor during cervical ripening occurred in 55.4% of patients. A cesarean section was necessary in 22% of cases. This rate was both significantly related to the initial Bishop score and to the Bishop score at the end of the procedure. Patient with induced labor during the cervical ripening had a significantly lower cesarean section rate compared to these who needed induction with oxytocin (10.7% versus 33.8%; p < 0.01). The uterine hyperstimulation rate was 1.6%. A 1 min Apgar score less than 7 occurred in 1.1% of neonates.


CONCLUSIONS
Our results do not demonstrate benefit of repeated administration comparison to a single administration described in literature. Maternal and neonatal morbidity is low in this study but cervical ripening should be used only when pregnancy disorders require prompt delivery within twenty-four hours.
Panel
P
P
Service de Gynécologie-Obstétrique, CHU, Poitiers.
Bascou
V
V
de Meeus
J B
JB
Magnin
G
G
D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects* / Q000502:physiology; D002585:Cesarean Section; D015232:Dinoprostone / Q000627:therapeutic use*; D005260:Female; D005782:Gels; D005865:Gestational Age; D006801:Humans; D007751:Labor, Induced / Q000379:methods*; D010120:Oxytocics / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies
D005782:Gels; D010120:Oxytocics; D015232:Dinoprostone